Filing step-change
BAFNAPH · 2026-10
Quarterly observations that moved versus the prior period in 2026-10. Facts only — not a call to act.
Narrative date 2026-10-21 · Evidence medium
Bafna Pharmaceuticals Sees Accelerating Gross Margin and Revenue Growth in Standard Shift Bafna Pharmaceuticals (BAFNAPH) experienced a significant improvement in its gross margin, accelerating to 31.57% in the latest standard shift, up from -3.38% in the previous quarter.
Raw Evidence
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 31.57 % | -3.38 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | -3.38 % | 5.46 | ▼ |
| REVENUE_GROWTH_YOY | -23.2 % | -97.9 | ▲ |
Cite this
Source: Samhati filing step-change for BAFNAPH (2026-10). Observation: Bafna Pharmaceuticals Sees Accelerating Gross Margin and Revenue Growth in Standard Shift Bafna Pharmaceuticals (BAFNAPH) experienced a significant improvement in its gross margin, accelerating to 31.57% in the latest standard shift, up from -3.38% in the previous quarter. Evidence quality: medium. Not investment advice — no buy, sell, or hold recommendation. Full narrative (Pro): https://samhati.ai/pricing Page: https://samhati.ai/stock/bafnaph/q/2026-10
Other periods